{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017382","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.890262+00:00","generated_at":"2026-06-23T23:57:56.963905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium Q2 net loss $14.1M (-$0.41/sh); cash $57.6M; clinical pipeline on track","bullets":["Net loss $14.1M, or $(0.41) per share, vs $9.2M ($0.31) in Q2 2021; R&D spend $9.5M.","Cash, cash equivalents and short-term investments $57.6M as of June 30, 2022.","Phase 3 EQUATOR study of itolizumab in aGVHD continues enrollment; interim data from lupus nephritis study expected mid-2022.","Phase 2 study of EQ101 in alopecia areata and Phase 1 study of EQ102 in celiac disease expected to initiate 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017382","json":"https://secwatch.observer/filing/0000950170-22-017382.json","markdown":"https://secwatch.observer/filing/0000950170-22-017382.md","text":"https://secwatch.observer/filing/0000950170-22-017382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/0000950170-22-017382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/eq-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:57:56.963905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}